1. Home
  2. ALLO
  3. Earnings

AI Earnings Predictions for Allogene Therapeutics Inc. (ALLO)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

+0.32%

$1.19

0% positive prob.

5-Day Prediction

-13.04%

$1.03

0% positive prob.

20-Day Prediction

-15.66%

$1.00

0% positive prob.

Price at prediction: $1.19 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL +0.32% -13.04% -15.66% 100.0% Pending
Q2 2026 SELL +0.32% -13.04% -15.66% 100.0% Pending
Q1 2026 SELL +1.16% -12.50% -15.30% 100.0% -18.45%
Q4 2025 SELL +1.34% -10.05% -14.28% 58.5% Pending
Q3 2025 BUY +2.67% +6.87% +5.48% 100.0% +12.79%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

+0.32%

$1.19

Act: -4.62%

5D

-13.04%

$1.03

20D

-15.66%

$1.00

Price: $1.19 Prob +5D: 0% AUC: 1.000
0001628280-26-071040

EX-99.1

2 allo-20260930xexx991q326.htm

EX-99.1

Document

Exhibit 99.1

Allogene Therapeutics Reports Third Quarter 2026

Financial Results and Business Update

•Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):

◦ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-Pacific

◦Next ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial Enrollment Completion Expected by Year-End 2027

◦Appointed Cell Therapy Commercialization Veteran Rocio Manghani, MPH, as Vice President, Market Access, Evidence & Strategy

◦Investor Event at ASH to Focus on Cema-cel’s Potential to Overcome Barriers to Autologous CAR T Adoption

•Phase 1 RESOLUTION Trial in Autoimmune Disease:

◦Presentation at ACR Convergence (November 9) to Expand on Published Nine-Patient Abstract with Additional Patients, Longer Follow-Up Across Three ALLO-329 Dose Levels and Three Lymphodepletion Approaches

◦Updated Results to Highlight ALLO-329's Emerging Safety and Clinical Activity, Including a Focused Assessment of Treatment Responses in Systemic Sclerosis (Scleroderma) and New Insights into the Role of Lymphodepletion

•Clinical Progress and Next-Generation Innovation

◦Two Invited Presentations at SITC 2026 will Highlight Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune Disease

◦Preclinical Poster to Showcase Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Showcasing Continued Innovation with Dagger® Technology

•Ended the Third Quarter of 2026 with $388.9 Million in Cash, Cash Equivalents and Investments

•Conference Call and Webcast Scheduled for Today at 2:00 p.m. PT/5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., November 5, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.

“CAR T has transformed what's possible in medicine, but toxicity and treatment complexity have kept its full potential out of reach for too many patients,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene. “We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care. At the same time, our ALLO-329 data set to be released next week will begin to address an equally important question in autoimmune disease: whether we can deliver meaningful clinical benefit with less reliance on chemotherapy-based conditioning. Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”

Cema-Cel: Pivotal ALPHA3 Trial in 1L Consolidation in LBCL

Cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, the first pivotal, randomized trial in LBCL designed to assess whether minimal residual disease (MRD)-guided treatment following first-line therapy can delay or prevent clinical relapse.

Enrollment momentum continues, supported by expanded site participation, increasing MRD screening activity, strong investigator engagement, and brisk enrollment in the Asia-Pacific region following the positive interim futility analysis reported earlier this year. The growing ALPHA3 network includes community oncology practices, where the majority of patients with LBCL receive treatment, reinforcing the potential for cema-cel to expand CAR T access beyond traditional treatment centers.

Early clinical experience has demonstrated the feasibility of outpatient cema-cel administration, including at community practices with limited or no prior CAR T experience. Together with the integration of MRD testing to identify patients at risk of relapse, these findings support the potential for ALPHA3 to establish a new treatment paradigm that brings CAR T earlier in the course of disease and closer to where patients receive care.

The Company continues to anticipate its next clinical update in mid-2027, with trial enrollment expected to be completed by year-end 2027.

Cema-Cel: Advancing Commercial Readiness and Patient Access

As the ALPHA3 program advances, Allogene has begun laying the groundwork for potential commercialization of cema-cel, with an early focus on payer coverage, reimbursement and treatment-site readiness to support broader patient access. To lead these efforts, the Company appointed Rocio Manghani, MPH, as Vice President, Market Access, Evidence & Strategy. Ms. Manghani brings extensive cell therapy commercialization experience from Kite, Gamida Cell and

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 12, 2026 · 100% conf.

AI Prediction SELL

1D

+0.32%

$2.07

Act: -3.88%

5D

-13.04%

$1.79

20D

-15.66%

$1.74

Price: $2.06 Prob +5D: 0% AUC: 1.000
0001628280-26-056198

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K SELL

May 13, 2026 · 100% conf.

AI Prediction SELL

1D

+1.16%

$2.36

Act: -8.15%

5D

-12.50%

$2.04

Act: -18.45%

20D

-15.30%

$1.97

Act: -19.31%

Price: $2.33 Prob +5D: 0% AUC: 1.000
0001628280-26-034583

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1784466576.b5f459a4

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Allogene Therapeutics Inc. (ALLO) Earnings

This page provides Allogene Therapeutics Inc. (ALLO) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ALLO's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: